
Michael J Robertson MD
Hematologic Oncology
Professor of Medicine, Indiana University
Join to view full profile
535 Barnhill Dr# ROUTE473Indianapolis, IN 46202
Phone+1 317-944-5000
Fax+1 317-944-3684
Dr. Robertson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael J. Robertson is a hematologic oncologist based in Indianapolis, IN. He completed his residency in Internal Medicine at the University of Chicago and fellowship in Medical Oncology at the Dana-Farber Cancer Institute. Dr. Robertson's extensive experience is further highlighted through his numerous publications in reputable journals, often cited by his peers, and involvement in clinical trials, such as those focused on Diffuse Large B Cell Lymphoma and hematologic cancers or solid tumors. His specialty and subspecialty lie in Oncology, particularly Hematologic Oncology.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1990
University of ChicagoResidency, Internal Medicine, 1984 - 1987
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1984
Certifications & Licensure
IN State Medical License 1996 - 2027
IL State Medical License 1984 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2014-2015
- CMS Meaningful Use Stage 1 Certification P2 Sentinel, Cerner Corporation, 2014-2015
- CMS Meaningful Use Stage 1 Certification FirstNet and Cerner Healthe, Cerner Corporation, 2014-2015
Clinical Trials
Publications & Presentations
PubMed
- 4 citationsA randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.Catherine S Diefenbach, Opeyemi Jegede, Victoria Wang, Stephen M Ansell, Lale Kostakoglu
Blood. 2026-04-30 - Editorial: Innovative immunotherapy strategies for enhanced treatment of Hodgkin and non-Hodgkin lymphomas.Michael J Robertson, Eric Vivier, Penny Fang
Frontiers in Immunology. 2025-01-01 - 47 citationsPost-transplant lymphoproliferative disorder: Update on treatment and novel therapies.Suheil Albert Atallah-Yunes, Omar Salman, Michael J Robertson
British Journal of Haematology. 2023-05-01
Grant Support
- Mechanisms Of STAT4 Deficiency In The Immune System Of Cancer PatientsNational Cancer Institute2007–2011
- Recombinant Human Interleukin-18 For Treatment Of A Patient With MetastaticNational Center For Research Resources2005
- Rhu IL 12 After High Dose &Autologous Hematopoietic Stem CellsNational Center For Research Resources1999–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: